Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine PK, pharmacogenomics, and exposure–response in systemic lupus erythematosus
ChiCTR2300070628Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxychloroquine in systemic lupus erythematosus (SLE), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: SLE Disease Activity Index (SLEDAI), Whole blood concentration of hydroxychloroquine and metabolites and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2300070628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070628.